Xevudy, which was part of the deal, has already seen restrictions on its use due to diminished efficacy against Omicron. Plus, Ocugen is back in the game as the FDA has released the clinical hold on its Phase II/III vaccine trial, while Pfizer/BioNTech release new booster shot data for Comirnaty in children aged 6 months-5 years.

Momentum for Dr Reddy’s in China as a string of approvals including for lenalidomide come through, while it appears to be on an even keel in Russia, a market where several foreign firms have cutback activities in the wake of the Ukraine conflict. Will the Indian firm’s Russia strategy payback?

Momentum for Dr Reddy’s in China as a string of approvals including for lenalidomide come through, while it appears to be on an even keel in Russia, a market where several foreign firms have cutback activities in the wake of the Ukraine conflict. Will the Indian firm’s Russia strategy payback?

In light of the Russia-Ukraine conflict, Scrip looks at data to gauge if manufacturing partners for COVID-19 vaccine Sputnik V or Light, in India, China and Korea could be left holding unsold inventory earmarked for exports